search
Back to results

The Immunomodulatory Effects of Phlebotomy

Primary Purpose

Anemia

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Phlebotomy
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Anemia focused on measuring anemia, blood withdrawal, phlebotomy, innate immunity, Immune reponse

Eligibility Criteria

18 Years - 35 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Male
  • Age >18 and <36 years
  • Healthy as concluded from medical history

Exclusion Criteria:

  • Having donated blood to the blood bank within one year preceding phlebotomy
  • Significant blood loss from trauma within one year preceding phlebotomy
  • Having lost > 100 ml of blood due to any cause, within 3 months preceding phlebotomy (not counting blood withdrawn during screening visit)
  • Having lost > 50 ml of blood due to any cause, within 1 month preceding phlebotomy (not counting blood withdrawn during screening visit)
  • Having lost >20 ml blood due to any cause, within 1 week preceding phlebotomy (not counting blood withdrawn during screening visit)
  • Family history of thallasemia, sickle cell disease, hereditary hemochromatosis, or iron refractory iron deficiency anemia
  • Signs of history of infection within 2 weeks preceding phlebotomy
  • History of frequent vasovagal response

Sites / Locations

  • Radboudumc

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Phlebotomy

Arm Description

Subjects in this arm will undergo phlebotomy of 500 mL of blood.

Outcomes

Primary Outcome Measures

ex vivo TNF-afpha production of whole blood in reponse to incubation with E. Coli LPS
Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.

Secondary Outcome Measures

ex vivo IL6 and IL-10 production of whole blood in response to incubation with E.Coli LPS
Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.
Changes in hemoglobin, hematocrit, white blood cell count and differential
Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following the withdrawal of 500 ml of blood at the blood bank
Changes in hemoglobin, hematocrit, white blood cell count and differential
Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following phlebotomy
Changes in plasma hepcidin
Plasma hepcidin concentration will be determined at various time points during the 28 days of follow-up, following phlebotomy
Changes in other markers of iron homeostasis (serum iron, transferrin saturation, ferritin)
Changes in parameters of iron homeostasis will be determined at various time points during the 28 days of follow-up, following phlebotomy
Adverse Events
Adverse Events will be assessed with every visit

Full Information

First Posted
January 8, 2014
Last Updated
January 8, 2014
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02031614
Brief Title
The Immunomodulatory Effects of Phlebotomy
Official Title
The Immunomodulatory Effects of Phlebotomy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2014
Overall Recruitment Status
Unknown status
Study Start Date
January 2014 (undefined)
Primary Completion Date
May 2014 (Anticipated)
Study Completion Date
May 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Although phlebotomy is routinely performed in blood donors, and seemingly does not have significant health risks, it is highly relevant to know what the effect of phlebotomy is on immunity. Alterations in immunity due to phlebotomy could have beneficial effects, like the suppression of the low grade inflammatory process that contributes to atherosclerosis, but in theory could also contribute to a suppressed innate immune response that could increase the risk of infection. This is not only relevant for blood donors, but also for patients suffering from blood loss and for daily clinical practice in which blood is routinely drawn of patients for laboratory determinations.
Detailed Description
The loss of blood by haemorrhage or routine phlebotomy as performed during blood donation by healthy volunteers, has large effects on systemic iron homeostasis. The relative shortage of erythrocytes after blood loss is compensated for by increasing the production of new red cells by the bone marrow. As iron is needed for effective haemoglobin synthesis, the transport of iron to the bone marrow needs to be increased. This is accomplished by the suppression of hepcidin production in the liver. Hepcidin is the central regulator of iron homeostasis. It can regulate serum iron levels effectively by downregulating iron channel ferroportin on iron exporting cells. Hepcidin production is increased in response to inflammation en high systemic iron content, and is suppressed by increased erythrocyte production, hypoxia, anemia, and low systemic iron content. Therefore, blood loss leads to hepcidin suppression, increased release of iron into the circulation and decrease of iron stores. Alterations in iron metabolism can have immunomodulatory effects. The intra cellular iron content in macropahges and monocytes, has shown pro-inflammatory effects in several investigations. Hepcidin is reported to have pro-inflammatory effects in some reports, and anti-inflammatory effects in others. Although phlebotomy is routinely performed in blood donors, and seemingly does not have significant health risks, it is highly relevant to know what the effect of phlebotomy is on immunity. Alterations in immunity due to phlebotomy could have beneficial effects, like the suppression of the low grade inflammatory process that contributes to atherosclerosis, but in theory could also contribute to a suppressed innate immune response that could increase the risk of infection. This is not only relevant for blood donors, but also for patients suffering from blood loss and for daily clinical practice in which blood is routinely drawn of patients for laboratory determinations. Objective: To assess the ex vivo cytokine production of whole blood during 28 days after phlebotomy (routine withdrawal of 500 ml of blood). Study design: Intervention study in 10 healthy male volunteers. Study population: 10 healthy male volunteers in the age of 18-35 years. Intervention (if applicable): Withdrawal of 500 mL of blood at the blood bank (Sanquin, Nijmegen, The Netherlands). Main study parameters/endpoints: Ex vivo cytokine production of whole blood, drawn on day -1, 0, 1, 3, 5, 7, 14, 21, 28. Hemoglobin, hematocrit, white blood cell count and differential Hepcidin Iron parameters (serum iron, transferrin saturation, ferritin) Nature and extent of the burden and risks associated with participation, benefit and group relatedness: 10 healthy young male volunteers will be included in this study. The study consists of 10 visits: 1 screening visit and 9 follow-up visits. The screening visit consists of a medical history questionnaire. On day 0, Phlebotomy of 500 ml of blood will be performed at the Sanquin blood bank, Nijmegen according to normal procedures. Risks associated with phlebotomy are, discomfort during puncture, light-headedness, orthostatic hypotension, vasovagale response, and hematoma at the puncture site. On day -1, 0, 1, 3, 5, 7, 14, 21 and 28, a volume of 7 mL of blood will be drawn by venapuncture. Associated risks are discomfort during puncture , vasovagale response, and hematoma at the puncture site.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia
Keywords
anemia, blood withdrawal, phlebotomy, innate immunity, Immune reponse

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phlebotomy
Arm Type
Experimental
Arm Description
Subjects in this arm will undergo phlebotomy of 500 mL of blood.
Intervention Type
Procedure
Intervention Name(s)
Phlebotomy
Intervention Description
Withdrawal of 500 mL of whole blood.
Primary Outcome Measure Information:
Title
ex vivo TNF-afpha production of whole blood in reponse to incubation with E. Coli LPS
Description
Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.
Time Frame
1 day before till 28 days after phlebotomy
Secondary Outcome Measure Information:
Title
ex vivo IL6 and IL-10 production of whole blood in response to incubation with E.Coli LPS
Description
Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.
Time Frame
1 day before till 28 days after phlebotomy
Title
Changes in hemoglobin, hematocrit, white blood cell count and differential
Description
Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following the withdrawal of 500 ml of blood at the blood bank
Time Frame
1 day before till 28 after phlebotomy
Title
Changes in hemoglobin, hematocrit, white blood cell count and differential
Description
Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following phlebotomy
Time Frame
1 day before till 28 after phlebotomy
Title
Changes in plasma hepcidin
Description
Plasma hepcidin concentration will be determined at various time points during the 28 days of follow-up, following phlebotomy
Time Frame
1 day before till 28 after phlebotomy
Title
Changes in other markers of iron homeostasis (serum iron, transferrin saturation, ferritin)
Description
Changes in parameters of iron homeostasis will be determined at various time points during the 28 days of follow-up, following phlebotomy
Time Frame
1 day before till 28 after phlebotomy
Title
Adverse Events
Description
Adverse Events will be assessed with every visit
Time Frame
1 day before till 28 after phlebotomy

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male Age >18 and <36 years Healthy as concluded from medical history Exclusion Criteria: Having donated blood to the blood bank within one year preceding phlebotomy Significant blood loss from trauma within one year preceding phlebotomy Having lost > 100 ml of blood due to any cause, within 3 months preceding phlebotomy (not counting blood withdrawn during screening visit) Having lost > 50 ml of blood due to any cause, within 1 month preceding phlebotomy (not counting blood withdrawn during screening visit) Having lost >20 ml blood due to any cause, within 1 week preceding phlebotomy (not counting blood withdrawn during screening visit) Family history of thallasemia, sickle cell disease, hereditary hemochromatosis, or iron refractory iron deficiency anemia Signs of history of infection within 2 weeks preceding phlebotomy History of frequent vasovagal response
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
L T van Eijk, MD, MSc
Phone
+31 24 3653879
Email
L.vanEijk@Radboudumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
P Pickkers, MD, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboudumc
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500 HB
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
L T van Eijk, MD, MSc
Phone
+31 24 3617273
First Name & Middle Initial & Last Name & Degree
P Pickkers, MD, PhD
First Name & Middle Initial & Last Name & Degree
L T van Eijk, MD, MSc

12. IPD Sharing Statement

Learn more about this trial

The Immunomodulatory Effects of Phlebotomy

We'll reach out to this number within 24 hrs